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Quiescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection despite effective antiret-
roviral therapy (ART) can fuel rebound viremia after ART interruption and is a central obstacle to the cure of HIV infection. The 
induction of quiescent provirus is the goal of a new class of potential therapeutics, latency reversing agents (LRAs). The discovery, 
development, and testing of HIV LRAs is a key part of current efforts to develop latency reversal and viral clearance strategies to 
eradicate established HIV infection. The development of LRAs is burdened by many uncertainties that make drug discovery difficult. 
The biology of HIV latency is complex and incompletely understood. Potential targets for LRAs are host factors, and the potential 
toxicities of host-directed therapies in individuals that are otherwise clinically stable may be unacceptable. Assays to measure latency 
reversal and assess the effectiveness of potential therapeutics are complex and incompletely validated. Despite these obstacles, novel 
LRAs are under development and beginning to enter combination testing with viral clearance strategies. It is hoped that the steady 
advances in the development of LRAs now being paired with emerging immunotherapeutics to clear persistently infected cells will 
soon allow measurable clinical advances toward an HIV cure.
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HUMAN IMMUNODEFICIENCY VIRUS CURE 
AND THE CHALLENGE OF PERSISTENT HUMAN 
IMMUNODEFICIENCY VIRUS INFECTION
The pandemic of human immunodeficiency virus type 1 (HIV-
1) infection has swept across societies with devastating effect 
over the last decades. In response, the scientific community has 
met the emergence of this zoonosis with remarkable force and 
innovation. An unprecedented collaboration with the commu-
nities affected by HIV and the pharmaceutical industry has led 
to modern antiretroviral therapy (ART) capable of conferring 
lifelong control of disease and stable health [1].
The implementation of ART across the world appears to have 
begun to blunt the spread of new cases of HIV infection, and 
there is evidence that the expansion of ART as prevention may 
have even greater impact [2]. However, HIV infection can per-
sist for decades despite clinically successful ART, due at least to 
the persistence of latent HIV infection within long-lived resting 
memory CD4+ T cells [3–6]. These latent reservoirs are imper-
vious to ART and unaffected by the immune system. Therefore, 
most agree that treatment approaches that allow HIV eradica-
tion or drug-free remission would add a critical element to the 
efforts to resolve the HIV pandemic. Despite the best efforts of 
preventive and vaccine strategies, it is likely that there will be 
large populations of HIV-infected people across the world for 
decades to come. Focused strategies that could eradicate estab-
lished infection could relieve the societal and personal burden 
of decades of chronic medical care and suppressive, lifelong 
antiviral therapy for many of these people.
Latent infection is established within days of infection and, 
in fact, appears to be established in a small fraction of the very 
first cells that become infected [7]. Latency decays very slowly 
with a half-life of 40–44 months, necessitating lifelong ART to 
suppress reignition of infection [8]. Although early administra-
tion of ART limits HIV replication and is associated with lower 
total and integrated HIV DNA and lower frequency of latent 
infection [9, 10], this is a clinically challenging maneuver to 
implement broadly.
Therefore a detailed understanding of the phenomena that 
allows HIV infection to persist for years despite potent ART is 
needed to guide the development of strategies that might some-
day safely and efficiently clear HIV infection. Proviral latency, 
the persistence of quiescent but replication-competent provirus 
in resting CD4+ T lymphocytes and to a lesser extent in other 
cell populations, is a central problem that must be addressed by 
any effort to clear persistent HIV infection [11].
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Host cell molecular mechanisms maintain the quiescence of 
HIV gene expression in infected resting CD4+ T lymphocytes 
and could therefore serve as therapeutic targets for disrupting 
latency. The recognition of this latent reservoir and its cellu-
lar regulation led initially to attempts to target persistent HIV 
infection through latency reversal using small molecules capa-
ble of inducing expression of the HIV provirus [12, 13]
Although several groups have demonstrated successful rever-
sal of latency in vivo, as measured by increases in cell-associated 
HIV RNA expression, these successes have not been marked by 
a parallel and persistent reduction in replication-competent 
HIV or other measures of persistent infection [14–17]. This has 
led to the current clearance strategy model, invoking the use of 
latency reversing agents (LRAs) in parallel with immune-medi-
ated clearance of infected cells.
PERSISTENCE PART I: INCOMPETENT RESERVOIRS 
OF FOSSILIZED HUMAN IMMUNODEFICIENCY VIRUS
As HIV enters a new target cell, it must contend with a hos-
tile environment designed to thwart its replication. The virion 
will carry APOBEC enzymes, most notably APOBEC3G, pack-
aged within the virion by the producer cell. These RNA-editing 
enzymes, an innate immune defense against RNA viruses, can 
antagonize HIV replication through cytidine deamination, 
resulting in hypermutation of the viral DNA genome, as well 
as interference with HIV reverse transcription and integra-
tion [18]. Given the additional effects of the error rates of the 
HIV reverse transcriptase and the degrading effects of host cell 
nucleases, the vast majority of HIV reverse-transcriptase prod-
ucts are incomplete, are circularized, fail to integrate, or are 
hypermutated. This predominance of HIV nucleic acid that per-
sists in cells that were infected but are now unable to produce 
replication-competent HIV poses a challenge for efforts both to 
measure the frequency of persistent HIV infection and to assess 
the effects of LRAs that are under development [19, 20].
Studies have shown the establishment of HIV DNA within 
cells early in the course of infection despite initiation of ART 
during acute infection and that the burden of DNA falls and then 
plateaus during prolonged ART. However, such HIV DNA inte-
grants are only a marker that the cell has been infected and that 
reverse transcription and integration have occurred. However, 
again because of the potency and efficacy of innate immunity 
enforced by the ApoBEC system, the vast majority of these HIV 
DNA genomes encode lethal mutations or deletions, and HIV 
DNA forms are detected approximately 300-fold more often 
than the frequency of recovery of replication-competent HIV 
[19]. Therefore, although HIV DNA levels can provide a gross 
overall comparative measure of past infection events in a pool 
of cells, such measures are blunt tools for the assessment of HIV 
clearance strategies after interventions. Depletions of HIV DNA 
have been seen following general T-cell ablative strategies, such 
as bone marrow transplantation [21, 22], that have depleted total 
T-cell populations regardless of their carriage of either defec-
tive HIV genomes or truly latent HIV. However, should future 
strategies be developed that selectively clear cells harboring cells 
carrying functional viral genomes, HIV DNA assays will per-
sistently detect innocuous, defective HIV DNA templates.
Nevertheless, quantitative polymerase chain reaction (qPCR) 
measures of total or integrated HIV DNA are the most commonly 
used, straightforward, and tractable method to quantify durable 
HIV infection [23]. HIV DNA is primarily detected in 2 subsets 
of memory CD4+ T cells, central memory CD4+ T cells (TCM) 
and transitional memory CD4+ T cells (TTM) [24]. Transitional 
memory CD4+ T cells are characterized by the expression of 
CD27 but lack expression of the lymph node homing receptor 
CCR7, whereas TCM CD4+ T cells express both CD27 and CCR7. 
However, when replication-competent HIV, rather than HIV 
DNA, is rigorously assessed, only the central memory CD4+ 
T-cell compartment has been shown to be a durable, sizable res-
ervoir of latent but persistent HIV infection [11].
Potential foci of durable, latent infection within the T-cell 
compartment have been recently identified. Pallikkuth et al 
found that within circulating TCM, the CXCR5+ subset desig-
nated peripheral T follicular helper (pTfh) cells preferentially 
harbor HIV DNA in virologically suppressed HIV-infected 
patients [25]. This CXCR5+ subset of pTfh cells appears to be 
highly susceptible to HIV. In HIV-infected participants, pTfh 
cells can be induced to express HIV p24 Gag protein, suggest-
ing that frequencies of inducible HIV p24 in pTfh cells could 
be used to monitor HIV reservoirs in blood. However, Banga 
et al found higher levels of cell-associated HIV RNA in lymph 
node Tfh (LN-Tfh ) cells than in TCM subsets but detected no 
antigen-positive Tfh cells after 3 years of ART [26]. Therefore 
this infected cell population may decay with time, or as these 
effector Tfh cells may transition to durable circulating memory 
cells, such cells may become a component of the viral reservoir. 
The true persistence of latent infection within effector Tfh cells 
requires further definition.
Similarly, in T-cell populations not distinguished by their acti-
vation status, the immune checkpoint markers LAG-3, PD-1, and 
TIGIT have been found to be preferentially present on cells that 
contain HIV DNA integrants and can express HIV RNA [27]. The 
stable persistence of these populations over time on ART remains 
to be demonstrated, as does the persistence of quiescent but repli-
cation-competent HIV within them. Further studies must define 
whether or not such cells comprise a population of cells that per-
sistently carry innocuous, defective HIV DNA templates or latent 
viral genomes capable of sparking rebound viremia.
PERSISTENCE PART II: CELLS THAT CARRY 
LATENT BUT REPLICATION-COMPETENT HUMAN 
IMMUNODEFICIENCY VIRUS
Persistence of virus in HIV-infected patients receiving potent 
antiretroviral therapy was conclusively demonstrated in 1997, 
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when rare, integrated, replication-competent HIV was recov-
ered from resting CD4 memory T cells [3–5]. To date this reser-
voir remains the most widely studied and best understood cause 
of viral persistence. The stability and slow decay of the reservoir 
has been long documented, and findings were recently precisely 
reproduced in a cohort studied 10 years later on more modern 
ART [8, 28].
The molecular mechanisms that allow the establishment of 
persistent but quiescent proviral infection are incompletely 
defined. It has been long been assumed that resting T-cell infec-
tion occurs as an activated T cell is in the process of reverting 
to a resting state. While reverting to a resting phase, T cells 
can support the early phases of virus infection, such as reverse 
transcription, and integration, but later steps are blunted once 
the cell reaches a resting state [29]. Other studies have clearly 
shown the ability of resting cells to be directly infected by HIV, 
albeit inefficiently [30]. It has also been suggested that the 
effects of HIV infection on other cells may induce cytokine sig-
naling that renders resting T cells permissive for infection [31]. 
These mechanisms are not mutually exclusive, and indeed there 
are likely to be multiple pathways to the latent state. Further, 
although the majority of latent infections in patients who have 
received long-term suppressive ART exists in resting CD4 T 
cells, it still must be said that persistent, durable, but truly latent 
infection in other potential cellular reservoirs such as myeloid 
cells has not been completely ruled out [32].
But more recently another mechanism that may contribute 
to the stability of the population of cells latently infected with 
replication-competent proviruses has been demonstrated—that 
of cellular proliferation. Identical proviral sequences have been 
found in HIV-infected patients on long-term ART integrated at 
the same position in the host genome in multiple cells, consis-
tent with the derivation of these infected cells from a progeni-
tor clone through cellular proliferation [33, 34]. However, the 
replication competence of these proliferating clones remains in 
question. One study found that all of the 75 integrated genomes 
that were fully sequenced contained lethal mutations or dele-
tions and were replication incompetent [35]. However, this 
finding cannot be taken as definitive, as even a tiny fraction of 
proliferating but replication-competent HIV genomes could 
contribute substantially to viral persistence. Indeed an illustra-
tive case has already been painstakingly documented to refute 
this claim [36]. This issue is discussed in depth elsewhere in this 
supplement (Mullens et al).
Currently it is unclear whether the latent pool of infected TCM 
derives its great stability from the longevity of the latent state 
itself, from proliferative forces that maintain it, or from a bal-
ance of both effects. Regardless, once durable and suppressive 
ART is in force, persistent HIV infection decays slowly over 
time, as discussed above [8, 28], suggesting that the homeosta-
sis that is achieved between effects that deplete the latent reser-
voir and those that preserve it are in mild negative balance. This 
leads to the hypothesis that LRA strategies designed to make 
persistently infected cells vulnerable to clearance are required 
to speed the decay of the latent infection sufficiently to lead to 
its eradication.
LATENCY REVERSAL: THE RATIONALE FOR LATENCY 
REVERSING AGENTS
The precise accounting that adds up to the persistence of repli-
cation-competent HIV capable of fueling rebound viremia fol-
lowing the interruption of ART is hotly debated. Factors that 
may drive viral persistence above and beyond the longevity 
of quiescent, integrated, replication-competent HIV provirus 
include only the following:
1. The long-term persistence of an unknown, long-lived cell 
population that chronically expresses replication-competent 
HIV;
2. Cryptic, ongoing rounds of infection of cells—despite the 
presence of fully suppressive, clinically successful ART—re-
sulting in the de novo integration with fully replication-com-
petent provirus; and 
3. Homeostatic or dysregulated proliferation of infected cells 
encoding quiescent, integrated, replication-competent HIV 
provirus.
Without extensively reiterating the controversies in the litera-
ture, it can be said that the possibility of durable reservoirs of 
active HIV production [37] has thus far been most strongly 
rebuffed [38–40]. The potential presence of cryptic replication 
and ART sanctuaries [41] has been challenged by methodolog-
ical report from the same laboratory and other findings [42, 
43]. A  further report on cryptic replication has recently cap-
tured attention [44], but more recent rebuttals are now under 
peer review. However, the phenomenon of proliferation of cells 
encoding HIV proviruses has been clearly demonstrated [33, 
34], and although the proportion of these genomes that are 
replication competent requires further definition [35, 36], it 
seems most likely that cellular proliferation may contribute to 
persistent proviral infection.
Regardless of the final adjudication of these controversies, 
given the slow decay of persistent HIV infection on current 
ART [8, 28], it would seem logical that persistent HIV infection 
could be extinguished by the development and implementation 
of sufficiently safe and effective LRAs capable of enforcing HIV 
antigen expression within the latent HIV reservoir such that 
these viral sanctuaries are vulnerable to clearance by antiviral 
effector mechanisms, be they natural or engineered. The devel-
opment of such LRAs and their careful pairing with appropriate 
and effective viral clearance strategies defines the core chal-
lenges of current HIV cure research.
LRAs have been conceptualized as agents that specifically tar-
get host cell mechanisms that either (1) restrain proviral expres-
sion and allow or enforce proviral latency or (2) establish or 
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enforce latency as they are required for proviral expression and 
exist in relative deficiency or limiting concentration in latently 
infected cells. Because TCM that do not display significant cell 
surface levels of cell activation markers (“resting CD4+ T cells”) 
have been defined as the most predominant and most durable 
reservoir of latent HIV infection, it is within this cellular milieu 
that the relevant host cell mechanisms to be targeted by LRAs 
should be first defined.
Epigenetic silencing of HIV transcription is thus far the 
best-validated target for development of clinically testable 
LRAs. The “histone code” hypothesis holds that combinations 
of distinct modifications occurring at particular sites on the his-
tone tail direct which proteins are capable of interacting with 
histone–DNA complexes and determine gene activity [45, 46]. 
Already >50 enzymes are known that selectively modify the 
histone tail, thus providing the means to make a combinatorial 
histone code. Multiple signaling pathways result in enzymatic 
covalent modifications (eg, acetylation, phosphorylation, meth-
ylation) of specific amino acids in histone tail domains. These 
modifications do not simply make chromatin more or less 
accessible but inscribe biophysical marks on gene regions, sig-
nals for the ordered recruitment of complexes of regulatory fac-
tors that up- or downregulate gene expression. However, it must 
be remembered that host enzymes that regulate the modifica-
tion of histone proteins are also capable of modifying the activ-
ity of other cell proteins, so the cellular phenotypes that result 
after the activity of such enzymes is altered may be exceedingly 
complex. For example, histone acetylases act to allow the tran-
scriptional machinery access to the DNA template and compete 
with histone deacetylases that blunt transcription by reducing 
accessibility of DNA templates. But the acetylation or deacetyl-
ation of other host proteins can affect cytoskeletal structure or 
transcription factor complex formation and thus may affect 
other steps of proviral expression or virion production [47].
The role of histone deacetylases (HDACs) in the mainte-
nance of stable, nonproductive HIV infection has been well 
documented [48]. Consistent with a major role for HDACs in 
establishing HIV latency, many drugs that inhibit HDAC activ-
ity, such as trichostatin A and valproic acid [49, 50], are effective 
inducers of HIV transcription in latently infected cells.
Histone deacetylase inhibitors (HDACis) have been the most 
extensively tested in the clinic for their activity as HIV LRAs. 
The potent HDAC inhibitor vorinostat (VOR) induces HIV 
chromatin acetylation and promoter expression in cell lines 
and elicits virus production ex vivo from the resting CD4+ T 
cells of HIV-infected patients on suppressive ART. Importantly, 
this effect is achieved without cellular activation, upregulation 
of HIV coreceptors, or de novo HIV infection [51, 52]. Direct 
proof of concept of latency reversal has also been achieved in 
clinical studies, where a significant increase in cell-associated 
HIV RNA production was observed following in vivo admin-
istration of VOR to ART-suppressed patients [14]. This finding 
has been confirmed in several other studies using VOR as well 
as the HDACis panobinostat and romidepsin as LRAs [14–17].
Another epigenetic LRA target that is under investigation is 
the methylation of histones [53–58]. Although DNA methyl-
ation does not appear to play a critical role in HIV silencing 
in vivo [59], histone methyltransferase inhibitors (HMTis) and 
HDACis are reported to synergistically induce the expression of 
latent HIV, but studies have largely been performed in cell lines. 
These studies [60, 61] suggest that different levels of latency 
exist: “inducible latency,” in which provirus is largely restricted 
by deacetylated histones, and “locked latency,” in which addi-
tional modification such as histone and DNA methylation fur-
ther restrict proviral expression. Histone deacetylase inhibition 
alone may not be sufficient to disrupt locked latency. In a pri-
mary resting T-cell model of HIV latency, a potent and selective 
EZH2/EZH1 (enhancer of zeste 2 Polycomb repressive complex 
2 subunit 2 or 1) inhibitor, GSK343, reduced histone 3 trimeth-
ylation at lysine 27 (H3K27) at the HIV provirus in resting cells. 
Remarkably, this epigenetic change was not associated with 
increased proviral expression in latently infected resting cells. 
However, following the reduction in H3K27 at the HIV long 
terminal repeat, the expression of the provirus appeared sen-
sitized to subsequent exposure of the HDACi VOR, and both 
HIV gag RNA and HIV p24 antigen production was induced up 
to 2.5-fold greater by combined exposure than by VOR alone. It 
remains to be proven that such true mechanistic synergy in the 
reversal of HIV latency can be achieved in human studies by the 
combination of HMTis and HDACis.
The bromodomain and extraterminal domain  (BET) fam-
ily of proteins has also emerged as a potential target of LRAs, 
although mechanisms by which BET inhibitors act to induce 
HIV transcriptional reactivation may be multimodal. BET 
inhibitors, in development in the context of oncology and more 
recently immune inflammatory disease [62, 63], serve to block 
the ability of BET proteins to recruit and form multiprotein 
complexes with many roles in host gene and viral expression. 
BET inhibitors promote chromatin reorganization by inducing 
the expression of histone acetytransferases, HDACs, and his-
tone demethylases, while suppressing histone methyltransfer-
ases and multiple T-cell activation genes. Such inhibitors may 
also influence the activity of the HIV Tat transactivator protein 
[64]. Such agents have been examined in animal models but are 
yet to undergo testing in HIV-infected people.
Beyond epigenetic targets of LRAs, small molecules or sig-
naling molecules that alter metabolism of resting CD4 cells 
may be needed to effectively reverse HIV [65] latency. Because 
resting cells express relatively low levels of the coactivating fac-
tors NF-κB or NFAT, their induction may allow resumption 
of transcription by latent HIV proviruses [65, 66]. The critical 
viral transactivator, Tat, recruits a transcription complex that 
contains novel components, including the transcription elon-
gation factor P-TEFb [67, 68], and upregulation of the level of 
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the P-TEFb component CycT1 [69] or release of the P-TEFb 
complex from its regulatory complex may allow effective 
latency reversal [70]. Agents that act as protein kinase C ago-
nists can mediate such cellular alterations. These were among 
the first LRAs proposed, when Dean Hamer first promulgated 
the “shock and kill” hypothesis in 2004 [12]. Recently, the use 
of a novel pathway to induce NFkB signaling has been proposed 
[71]. Although there have been several studies reporting the 
LRA activity of protein kinase C agonists, both alone and in 
combination with other LRAs, few animal model studies have 
been reported, and a single human study was thwarted because 
effective levels of bryostatin could not be achieved [72].
Other molecular mechanisms that establish or enforce 
HIV latency have been reported. These include impaired HIV 
mRNA export in resting T cells [73], miRNAs that may impede 
HIV mRNA expression or translation, transcriptional interfer-
ence mediated by active upstream host promoters, and limiting 
amounts of other cellular kinases that may be critical to HIV 
transcriptional expression and induction [74]. However, ther-
apeutics to target these cellular events and serve as LRAs have 
not yet been defined.
Finally, LRAs whose mechanism of action is less clear have 
been reported. Toll-like receptor agonists [75, 76], thought to 
reverse latency in vivo through cellular signaling, are under 
investigation. Several high-throughput screens have been per-
formed and reported in industry research programs and aca-
demic collaborations. Some have yielded potential LRAs of 
either defined or unknown mechanisms of action, but none 
have yet been fully validated and are ready to enter human clin-
ical studies.
LATENCY REVERSING AGENTS: DEVELOPMENTAL 
CHALLENGES
The development and testing of HIV LRAs is fraught with sev-
eral unique challenges. The process of drug discovery involves 
the identification of a therapeutic target, followed by the syn-
thesis, characterization, screening, and assessment of lead com-
pounds that act on this target. Therapeutic advancement of 
LRAs is daunting because (1) few targets are well-validated, (2) 
effective LRA therapy may require agents with activity against 
multiple targets, (3) screening criteria that define effective in 
vivo activity are incompletely understood, and (4) assays to 
study and validate latency reversal in vivo are incompletely 
developed.
As discussed in the section above, there are several prom-
ising targets against which LRAs may be developed. However, 
because latency reversal is not a clinical or therapeutic end in 
and of itself, truly effective LRAs may only be defined when 
they can by themselves also induce measureable clearance 
of persistent HIV infection or, more likely, when they can be 
appropriately paired with viral clearance strategies that result 
in depletion of latency. As an intermediate step, it is rational 
to define LRAs as agents that can reverse latency as defined by 
upregulation of HIV expression in the best available model of 
in vitro latency, followed by validation of this activity in vivo 
in an animal model of HIV latency such as the HIV-infected 
humanized BLT mouse or the simian immunodeficiency 
virus–infected macaque. Ultimately, LRAs must be validated in 
human studies.
Initially, the reversal of latency was defined by upregulation 
of HIV expression in chronically infected T-cell lines such as 
ACH2 and U1 [77, 78]. However, these early models displayed 
restricted HIV expression due to defects in the Tat/TAR axis 
and were later replaced by improved models in Jurkat CD4+ T 
cells such as JLat and J89 [79–81].
Further, and most critically, the many mechanisms that 
restrict HIV gene expression appear to act largely independently. 
This was elegantly illustrated in the work of the Verdin labo-
ratory [80, 81], wherein different clonal isolates of the Jurkat 
CD4+ T-cell line model of latency were examined. Infected with 
the same HIV laboratory clone but with viral integrants in var-
ious genomic sites, these models of HIV latency presented a 
spectrum of responsiveness or lack thereof to different signals 
such as HDAC inhibition or the viral activator Tat.
Seeking to better represent the biology of latent proviral infec-
tion in an in vitro model system, a variety of primary cell mod-
els have been developed. As reviewed by Yang [82], a variety of 
methods for in vitro infection of primary CD4+ T cells allow 
infected cells to return to the resting state. These models allow for 
the laboratory study of primary, untransformed cells that have 
been infected in a polyclonal fashion by a variety of viral clones.
Seeking to assess the responsiveness of a number of these pri-
mary cell models of HIV latency to a variety of pathways and 
signals known to disrupt HIV latency, Spina, Planelles, and col-
leagues in the Martin Delaney CARE consortium performed a 
comprehensive comparison of 5 primary cell models and 4 J-Lat 
clones to the responses obtained in quantitative viral outgrowth 
assays in resting CD4+ T cells obtained from aviremic, ART-
treated, HIV-positive donors [83]. A panel of 13 stimuli known 
to reactivate HIV by defined mechanisms of action was selected. 
Disappointingly, no single in vitro cell model alone reflected 
precisely the ex vivo response characteristics of latently infected 
T cells derived from HIV-positive individuals. Rather, it seemed 
that the diversity of the biology of latency could only be encom-
passed by a diverse set of model systems. In a follow-up study, 
the role of integration site was analyzed across 5 primary cell 
models, and similarly, although the site of proviral integration 
appeared to contribute to HIV silencing, the location of a given 
proviral integrant did not by itself determine latency phenotype 
[84]. In summary, although the use of primary cell models of 
latency may be useful to better reflect the response of latent HIV 
to putative LRAs, there is currently no single in vitro model that 
accurately and comprehensively reflects the biological diversity 
of HIV latency.
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The complexity of the biology of HIV latency leads to a cor-
ollary challenge in the development of LRAs. Although the 
mechanisms that establish HIV latency and maintain proviral 
quiescence within the many biologically diverse cellular milieu 
that comprise the latent HIV reservoir are not fully understood, 
it is clear that effective reversal of latency will be a complex 
endeavor. Although the transcriptional activity of an individual 
provirus, in vivo or in any model system, is typically assessed 
in a snapshot of time, the regulation of HIV gene expression 
is complex and dynamic. A  cell that appears to be latently 
infected, lacking viral expression at one moment, may be active 
below the threshold of detection of the assay being used or may 
become active at a later moment in time. Indeed, the “noise” of 
basal HIV promoter expression and stochastic fluctuations in 
this level of expression have been elegantly described [85, 86]. 
Therefore, because of the dynamic state of the latent reservoir, 
latency reversal strategies should be evaluated in complex sys-
tems that can assess changes and responses in cells over time 
and following multiple rounds of single or combinatorial stim-
uli. Obviously, the number of possible conditions and combi-
nations may be too great to allow the experimental assessment 
of every possibility, and typical high-throughput screening 
approaches may have to give way to rationally designed screens, 
informed by our current understanding of mechanisms of cell 
and viral regulation.
Given the challenges of the available model systems, meth-
ods to allow the direct assessment of LRA activity in peripheral 
blood cells donated by ART-suppressed, HIV-infected people 
have been used. Archin et al first validated the activity of VOR 
by measuring changes in cell-associated unspliced HIV RNA 
message in multiple pools of circulating, resting CD4+ T cells. 
Multiple other assays of cell-associated HIV RNA have since 
been promulgated [87–89]. Comparison of these assays is an 
ongoing effort. Although such assays provide definitive proof 
of the induction of HIV transcription, at least in the cell pop-
ulation used in the assay, they are resource intensive and not 
suitable for high-throughput testing.
However, as reemphasized by the work of Ho and colleagues, 
the majority of integrated HIV genomes within the latent reservoir 
fail to express HIV RNA that can lead to virion production [20]. 
Therefore, because the induction of HIV RNA expression does not 
ensure that HIV proteins are properly translated and presented as 
viral antigens that might be recognized and cleared, novel assays 
have recently been presented that seek to detect cells presenting HIV 
proteins or antigen [90]. The challenges of measuring the frequency 
of latent, persistent HIV infection are discussed in greater depth 
elsewhere in this supplement (T. Henrich, S. Deeks, this issue).
Finally, our group has developed latency clearance assays 
using HIV-positive participants’ autologous CD4+ cells, viral 
isolates, and effector cells to demonstrate that LRAs act to 
induce sufficient viral antigen to allow for clearance of infection 
by effector mechanisms and to simultaneously demonstrate—at 
least in vitro—that effector mechanisms can operate effectively 
in the presence of LRAs [91, 92]. Looking forward, the effect of 
LRAs on immune effector function will be an important met-
ric to consider as latency reversal and viral clearance strategies 
are paired in animal model and human clinical testing. Already, 
groups have reported disparate effects of HDACis, for example, 
on the immune response, likely because of methodological dif-
ferences [91, 93, 94]. These effects will have to be carefully con-
sidered as LRA development moves forward.
CONCLUSIONS
The difficult work of attacking the latent reservoir of persistent 
HIV infection has begun. Much is to be learned about the biol-
ogy of HIV latency, but numerous promising directions for the 
development of LRAs have already emerged from our current, 
imperfect knowledge of HIV persistence. An array of novel 
assays has been developed and implemented in the past several 
years to allow the discovery and testing of LRAs, and improve-
ments in these tools will greatly accelerate the development of 
effective therapeutics. As both preclinical and clinical studies 
advance and tools and model systems are improved, progress 
should accelerate toward the goal of pairing safe and effective 
LRAs with immunotherapeutic strategies to clear persistent 
infection. It is a goal worthy of the effort that will be needed.
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